Yan Kaiguo, Wachsberger Phyllis, Yu Yan
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:769-72. doi: 10.1109/IEMBS.2009.5333814.
Molecular oxygen is the best known mediator of radiation damage during radiation therapy. This paper investigates techniques for enhancing tumor oxygenation by use of anti-angiogenic therapy for better radiosensitivity. A noninvasive monitoring technique, Acoustic radiation force (ARF)-induced optical spectroscopy, was proposed in this paper to track tumor oxygen changes during anti-angiogenic therapy. Male NCR-NUM nude mice bearing human U87 glioblastoma (ATCC) xenografts on the right hind limb were used for the study. An anti-angiogenic regimen using the drug AZD2171 (AsraZeneca) was found capable of improving tissue oxygenation during the first week of drug treatment. The optical spectroscopy technique was shown to be able to track tumor oxygenation changes during anti-angiogenic therapy, as verified by direct pO2 measurement. By using anti-angiogenic therapy to improve tumor oxygenation prior to radiotherapy, tissue oxygenation may be altered in a way that favors radiation therapy.
分子氧是放射治疗期间辐射损伤最广为人知的介质。本文研究了通过使用抗血管生成疗法来增强肿瘤氧合作用以提高放射敏感性的技术。本文提出了一种非侵入性监测技术,即声辐射力(ARF)诱导光学光谱法,以跟踪抗血管生成治疗期间肿瘤的氧变化。将右后肢携带人U87胶质母细胞瘤(ATCC)异种移植物的雄性NCR-NUM裸鼠用于该研究。发现使用药物AZD2171(阿斯利康)的抗血管生成方案能够在药物治疗的第一周改善组织氧合。如通过直接pO2测量所证实的,光学光谱技术显示能够跟踪抗血管生成治疗期间肿瘤的氧合变化。通过在放疗前使用抗血管生成疗法改善肿瘤氧合,组织氧合可能会以有利于放射治疗的方式发生改变。